UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 142

Sortiert nach

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma

Supportive care in cancer, 2021-11, Vol.29 (11), p.6973-6980

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in oncology, 2021-02, Vol.10, p.624661-624661

2021

Link zum Volltext

Verfügbarkeit prüfen

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma

Cancers, 2022-08, Vol.14 (17), p.4063

2022

Link zum Volltext

Verfügbarkeit prüfen

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

International journal of molecular sciences, 2022-11, Vol.23 (21), p.13332

2022

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

Cancers, 2021-09, Vol.13 (18), p.4566

2021

Link zum Volltext

Verfügbarkeit prüfen

Secondary syphilis mimicking malignancy: A case report and review of literature

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017-08, Vol.23 (8), p.576-578

2017

Link zum Volltext

Verfügbarkeit prüfen

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Cancer medicine (Malden, MA), 2019-06, Vol.8 (6), p.2802-2809

2019

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20051-e20051

2023

Link zum Volltext

Verfügbarkeit prüfen

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Blood, 2022-11, Vol.140 (Supplement 1), p.13248-13249

2022

Link zum Volltext

Verfügbarkeit prüfen

Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in NOVEL agents' era

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e20010-e20010

2022

Link zum Volltext

Verfügbarkeit prüfen

Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e20002-e20002

2022

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Case reports in hematology, 2016-01, Vol.2016, p.6745286-3

2016

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.5020-5020

2021

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.5022-5022

2021

Link zum Volltext

Verfügbarkeit prüfen

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Blood, 2021-11, Vol.138 (Supplement 1), p.4760-4760

2021

Link zum Volltext

Verfügbarkeit prüfen

Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Blood, 2018-11, Vol.132 (Supplement 1), p.5905-5905

2018

Link zum Volltext

Verfügbarkeit prüfen

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Blood, 2022-11, Vol.140 (Supplement 1), p.12585-12586

2022

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.2-2

2020

Link zum Volltext

Verfügbarkeit prüfen

MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S443-S443

2021

Link zum Volltext

Verfügbarkeit prüfen

MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S442-S442

2021

Link zum Volltext

Verfügbarkeit prüfen

Poster: MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S253-S253

2021

Link zum Volltext

Verfügbarkeit prüfen

Poster: MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S253-S253

2021

Link zum Volltext

Verfügbarkeit prüfen

Poster: MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S253-S253

2021

Link zum Volltext

Verfügbarkeit prüfen

MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S442-S442

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

Secondary syphilis mimicking malignancy: A case report and review of literature

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial

Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in NOVEL agents' era

Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment

MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era

Poster: MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era

Poster: MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Poster: MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment

MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Suchergebnisse filtern